400-9696-311 转1
400-9696-311 转3
400-9696-311 转4
400-9696-311 转5
400客服电话
购买数据产品
400-9696-311 转1
定制咨询业务
400-9696-311 转2
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
2021-12-10
FDA-2020-D-1301
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
This guidance provides recommendations for permitted daily exposures (PDEs) for three additional residual solvents: (1) 2-methyltetrahydrofuran, (2) cyclopentyl methyl ether, and (3) tert-butyl alcohol. This guidance is intended to recommend acceptable amounts for these residual solvents in pharmaceuticals for the safety of the patient. As part of the maintenance process for the ICH guidance for industry Q3C Impurities: Residual Solvents (December 1997), the Q3C PDE levels are added and revised as new toxicological data for solvents become available.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2020-D-1301.
摩熵医药2026-06-17
摩熵医药2026-06-09
赛柏蓝2026-06-01
深蓝观2026-05-22
赛柏蓝2026-04-24
摩熵医械2026-01-28
摩熵医械2026-01-13
摩熵医械2025-12-19
赛柏蓝2025-12-12
摩熵医械2025-11-28
2026-07-17
2026-07-15
2026-07-03
2026-07-03
2026-07-02
2026-06-30
2026-06-25
2026-06-24
2026-06-23
2026-06-15
2026-06-01
2026-06-01
2026-05-25
2026-05-20
2026-05-13
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2026-05-13
2026-05-13
2026-05-13
2026-05-13
2026-05-13
2026-05-08
2026-05-08
2026-05-08
2026-05-08
2026-05-07
2026-05-06
2026-05-05
2026-04-21
2026-04-20
2026-04-20